CA3092076A1 - Formes posologiques et procedes pour obtenir du bupropion enantiomeriquement enrichi ou pur - Google Patents
Formes posologiques et procedes pour obtenir du bupropion enantiomeriquement enrichi ou pur Download PDFInfo
- Publication number
- CA3092076A1 CA3092076A1 CA3092076A CA3092076A CA3092076A1 CA 3092076 A1 CA3092076 A1 CA 3092076A1 CA 3092076 A CA3092076 A CA 3092076A CA 3092076 A CA3092076 A CA 3092076A CA 3092076 A1 CA3092076 A1 CA 3092076A1
- Authority
- CA
- Canada
- Prior art keywords
- bupropion
- dosage form
- nnl
- human
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'utilisation de (S)-bupropion énantiomériquement enrichi ou d'un métabolite connexe en forme posologique est décrite. Le (S)-bupropion en forme posologique peut ne pas être enrichi de deutérium. Ces formes posologiques peuvent servir à l'administration orale pour traiter une condition, comme un trouble neuropsychiatrique, un rhume ou la toux, soulager la douleur, la dépendance ou une condition traitable à l'aide du (S)-bupropion pour atteindre un certain niveau de plasma ou paramètre pharmacocinétique d'un bupropion ou d'un métabolite du bupropion, et/ou améliorer les niveaux de plasma de dextrométhorphane. L'utilisation peut comprendre des dosages et/ou des fréquences de dosage en particulier.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US62/634,718 | 2018-02-23 | ||
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US62/794,469 | 2019-01-18 | ||
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| US62/809,480 | 2019-02-22 | ||
| PCT/US2019/019445 WO2019165379A1 (fr) | 2018-02-23 | 2019-02-25 | Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092076A1 true CA3092076A1 (fr) | 2019-08-29 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092076A Pending CA3092076A1 (fr) | 2018-02-23 | 2019-02-25 | Formes posologiques et procedes pour obtenir du bupropion enantiomeriquement enrichi ou pur |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (fr) |
| JP (3) | JP2021513998A (fr) |
| KR (3) | KR20210003091A (fr) |
| CN (2) | CN112087999A (fr) |
| AU (3) | AU2019223187B2 (fr) |
| BR (1) | BR112020017179A2 (fr) |
| CA (1) | CA3092076A1 (fr) |
| CL (1) | CL2020002166A1 (fr) |
| CR (1) | CR20200415A (fr) |
| EC (1) | ECSP20060179A (fr) |
| IL (2) | IL313368A (fr) |
| MA (1) | MA51914A (fr) |
| MX (2) | MX2020008704A (fr) |
| MY (1) | MY202993A (fr) |
| NI (1) | NI202000056A (fr) |
| NZ (1) | NZ767378A (fr) |
| PE (1) | PE20211752A1 (fr) |
| SG (1) | SG11202008056SA (fr) |
| WO (1) | WO2019165379A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210003091A (ko) * | 2018-02-23 | 2021-01-11 | 액섬 테라퓨틱스, 인크. | 거울상이성질체적으로 농후한 또는 순수한 부프로피온을 위한 투여 형태 및 방법 |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2022003346A (es) * | 2019-09-20 | 2022-04-11 | Axsome Therapeutics Inc | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| WO2025259728A1 (fr) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Composés et combinaisons de ceux-ci pour le traitement d'affections neurologiques et psychiatriques |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038502A1 (fr) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Utilisations pharmaceutiques de (+)-bupropion optiquement pur |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| KR101087464B1 (ko) * | 2003-08-08 | 2011-11-25 | 밸리언트 인터내셔널(바베이도스) 에스알엘 | 부프로피온 히드로클로라이드의 개질 방출형 정제 |
| WO2012118562A1 (fr) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions et méthodes de traitement de la dépression, du trouble de l'hyperactivité avec déficit de l'attention et d'autres troubles du système nerveux central au moyen de nouveaux composés de bupropione, et procédés de production et d'utilisation de nouveaux composés de bupropione et de formulations associées |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| KR20210003091A (ko) * | 2018-02-23 | 2021-01-11 | 액섬 테라퓨틱스, 인크. | 거울상이성질체적으로 농후한 또는 순수한 부프로피온을 위한 투여 형태 및 방법 |
-
2019
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 CA CA3092076A patent/CA3092076A1/fr active Pending
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/fr active Pending
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt not_active Application Discontinuation
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko not_active Ceased
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/fr not_active Ceased
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020017179A2 (pt) | 2020-12-22 |
| MX2020008704A (es) | 2020-12-07 |
| SG11202008056SA (en) | 2020-09-29 |
| MX2023009281A (es) | 2023-08-17 |
| AU2022204521B2 (en) | 2024-09-05 |
| MA51914A (fr) | 2020-12-30 |
| IL313368A (en) | 2024-08-01 |
| PE20211752A1 (es) | 2021-09-06 |
| IL276871B1 (en) | 2024-07-01 |
| KR20240091043A (ko) | 2024-06-21 |
| EP3755312A4 (fr) | 2022-03-16 |
| AU2022204521A1 (en) | 2022-07-21 |
| CN120827545A (zh) | 2025-10-24 |
| IL276871A (en) | 2020-10-29 |
| AU2019223187A1 (en) | 2020-09-17 |
| CN112087999A (zh) | 2020-12-15 |
| AU2024205858A1 (en) | 2024-09-05 |
| ECSP20060179A (es) | 2020-12-31 |
| AU2019223187B2 (en) | 2022-07-28 |
| NI202000056A (es) | 2021-01-11 |
| CR20200415A (es) | 2021-02-03 |
| KR20210003091A (ko) | 2021-01-11 |
| JP2021513998A (ja) | 2021-06-03 |
| MY202993A (en) | 2024-05-31 |
| KR20230075531A (ko) | 2023-05-31 |
| EP3755312A1 (fr) | 2020-12-30 |
| WO2019165379A1 (fr) | 2019-08-29 |
| IL276871B2 (en) | 2024-11-01 |
| JP2024075655A (ja) | 2024-06-04 |
| CL2020002166A1 (es) | 2020-10-23 |
| NZ767378A (en) | 2024-03-22 |
| JP2022153638A (ja) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11660273B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20210196704A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| AU2022204521B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20210177834A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11660274B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20190216800A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20190216801A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US10695304B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11179352B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11433035B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11331285B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20210330613A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20200222339A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20220249405A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20260014142A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| AU2020349419A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20240277635A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| BR122026004011A2 (pt) | Forma de dosagem e uso de (s)-bupropiona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200821 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250128 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250128 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250612 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251010 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251209 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251216 |